PGNX Progenics Pharmaceuticals Inc.

6.77
-0.06  -1%
Previous Close 6.83
Open 6.85
Price To book 5.37
Market Cap 475.42M
Shares 70,225,000
Volume 478,323
Short Ratio 4.17
Av. Daily Volume 1,165,700

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2/3 initiation announced December 7, 2016.
PyL
Prostate cancer
Pivotal Phase 2 trial resumed January 2015 following suspension of trial in 2010 due to lack of funding. Primary endpoint met - March 30, 2017. NDA filing due mid-2017.
Azedra
Pheochromocytoma
Phase 3 interim analysis completed December 22, 2016 by Data Monitoring Committee (DMC). Trial to continue.
1404
Help visualize prostate cancer by targeting prostate specific membrane antigen (PSMA)
Approved July 19 2016.
Oral RELISTOR
Chronic pain
Approved September 29, 2014.
Subcutaneous RELISTOR
Chronic pain
Abstract released at American Society of Clinical Oncology's 2014 Genitourinary Cancers Symposium Meeting in San Francisco in January 28 2014.
PSMA ADC
Cancer - metastatic castrate resistant prostate cancer (mCRPC).